Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Nemolizumab in Moderate-to-Severe Atopic Dermatitis
NCT03989206Phase 3Completed
- Sponsor
- Galderma
- Start
- Dec 2019
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Started Dec 2019; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03989206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03989206.